Paper41300302
The Roles of Sirt1 in Breast and Gynecologic Malignancies.
Ding J and 2 others. Biology (Basel), 2025. Cited by 5 papers, by iCite.
Cite this record
ConductScience Library. The Roles of Sirt1 in Breast and Gynecologic Malignancies. Papers, record 41300302. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41300302
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
Grants2
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| N/A | Internal funding | PubMed | ||
| N/A | Internal funding | PubMed |
Source PubMed
References190
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 22888282 | The genomics and genetics of endometrial cancer. | Adv Genomics Genet | 2012 | https://conductscience.org/library/papers/22888282 | PubMed |
| 2 | 30181620 | FR58P1a; a new uncoupler of OXPHOS that inhibits migration in triple-negative breast cancer cells via Sirt1/AMPK/β1-integrin pathway. | Sci Rep | 2018 | https://conductscience.org/library/papers/30181620 | PubMed |
| 3 | 25223731 | An exploratory double-blind, randomized clinical trial with selisistat, a SirT1 inhibitor, in patients with Huntington's disease. | Br J Clin Pharmacol | 2015 | https://conductscience.org/library/papers/25223731 | PubMed |
| 4 | 26004371 | Distinctive role of SIRT1 expression on tumor invasion and metastasis in breast cancer by molecular subtype. | Hum Pathol | 2015 | https://conductscience.org/library/papers/26004371 | PubMed |
| 5 | 30982660 | Loss of Sirtuin 1 Alters the Secretome of Breast Cancer Cells by Impairing Lysosomal Integrity. | Dev Cell | 2019 | https://conductscience.org/library/papers/30982660 | PubMed |
| 6 | 34808628 | Silent Information Regulator 1 Promotes Proliferation, Migration, and Invasion of Cervical Cancer Cells and Is Upregulated by Human Papillomavirus 16 E7 Oncoprotein. | Gynecol Obstet Invest | 2022 | https://conductscience.org/library/papers/34808628 | PubMed |
| 7 | 33438275 | Sirtuin 1 promotes autophagy and proliferation of endometrial cancer cells by reducing acetylation level of LC3. | Cell Biol Int | 2021 | https://conductscience.org/library/papers/33438275 | PubMed |
| 8 | 35252293 | Molecular Mechanism Underlying the Regulatory Effect of Vine Tea on Metabolic Syndrome by Targeting Redox Balance and Gut Microbiota. | Front Nutr | 2022 | https://conductscience.org/library/papers/35252293 | PubMed |
| 9 | 32902187 | Histone H3K9 and H3K14 acetylation at the promoter of the LGALS9 gene is associated with mRNA levels in cervical cancer cells. | FEBS Open Bio | 2020 | https://conductscience.org/library/papers/32902187 | PubMed |
| 10 | 36690678 | NAD+ supplementation limits triple-negative breast cancer metastasis via SIRT1-P66Shc signaling. | Oncogene | 2023 | https://conductscience.org/library/papers/36690678 | PubMed |
| 11 | 22017869 | Peptide switch is essential for Sirt1 deacetylase activity. | Mol Cell | 2011 | https://conductscience.org/library/papers/22017869 | PubMed |
| 12 | 6822361 | Two pathogenetic types of endometrial carcinoma. | Gynecol Oncol | 1983 | https://conductscience.org/library/papers/6822361 | PubMed |
| 13 | 36830834 | The Adipokine Visfatin Modulates Cancer Stem Cell Properties in Triple-Negative Breast Cancer. | Biomedicines | 2023 | https://conductscience.org/library/papers/36830834 | PubMed |
| 14 | 30217020 | A New Synthetic Histone Deacetylase Inhibitor, MHY2256, Induces Apoptosis and Autophagy Cell Death in Endometrial Cancer Cells via p53 Acetylation. | Int J Mol Sci | 2018 | https://conductscience.org/library/papers/30217020 | PubMed |
| 15 | 29992272 | A randomized placebo-controlled clinical trial of nicotinamide riboside in obese men: safety, insulin-sensitivity, and lipid-mobilizing effects. | Am J Clin Nutr | 2018 | https://conductscience.org/library/papers/29992272 | PubMed |
| 16 | 28498637 | β2-AR activation induces chemoresistance by modulating p53 acetylation through upregulating Sirt1 in cervical cancer cells. | Cancer Sci | 2017 | https://conductscience.org/library/papers/28498637 | PubMed |
| 17 | 23169992 | SIRT1 represses estrogen-signaling, ligand-independent ERα-mediated transcription, and cell proliferation in estrogen-responsive breast cells. | J Endocrinol | 2013 | https://conductscience.org/library/papers/23169992 | PubMed |
| 18 | 33649834 | SIRT1 and gynecological malignancies (Review). | Oncol Rep | 2021 | https://conductscience.org/library/papers/33649834 | PubMed |
| 19 | 22661383 | Expression of SIRT1 is associated with lymph node metastasis and poor prognosis in both operable triple-negative and non-triple-negative breast cancer. | Med Oncol | 2012 | https://conductscience.org/library/papers/22661383 | PubMed |
| 20 | 19595309 | Sirtuins and p53. | Adv Cancer Res | 2009 | https://conductscience.org/library/papers/19595309 | PubMed |
Cited by4
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 5 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42883867 | Targeting Aromatase and HDACs in Hormone Receptor-Positive Breast Cancer: Molecular Interplay, Endocrine Resistance and Therapeutic Opportunities. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/42883867 | PubMed |
| 42794654 | SIRT1 Promotes Breast Cancer Stem Cell-Associated Properties and Represents a Potential Therapeutic Target. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/42794654 | PubMed |
| 42577302 | Gut microbiota-derived butyrate and the SIRT1/FoxO1 axis: epigenetic-metabolic regulation of ovarian function in premature ovarian insufficiency-a comprehensive review. | Front Microbiol | 2026 | https://conductscience.org/library/papers/42577302 | PubMed |
| 42212122 | Post-translational modifications in retinoblastoma: mechanisms, immune regulation, and therapeutic opportunities. | Front Immunol | 2026 | https://conductscience.org/library/papers/42212122 | PubMed |
Genes4
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| FOXO1 | 2308 | PubTator's text mining | https://conductscience.org/library/genes/2308 | NCBI Gene |
| NFKB1 | 4790 | PubTator's text mining | https://conductscience.org/library/genes/4790 | NCBI Gene |
| SIRT1 | 23411 | PubTator's text mining | https://conductscience.org/library/genes/23411 | NCBI Gene |
| TP53 | 7157 | PubTator's text mining | https://conductscience.org/library/genes/7157 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/41300302
GET https://conductscience.org/api/papers/v1/41300302/references?page=2